National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 77129 [2022-27285]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 87, No. 241 / Friday, December 16, 2022 / Notices • R01 CA231940–01A1, ‘‘Regulation of Tet2 in programming mammary stem cell fate,’’ submitted to NCI, NIH, on 06/ 26/2018. • R01 CA233941–01, ‘‘DHA directs epigenetic programming in triplenegative breast cancer,’’ submitted to NCI, NIH, on 02/05/2018. • R01 GM121775–01, ‘‘The role of Tet2 regulation in directing mammary stem cell fate,’’ submitted to the National Institute of General Medical Sciences (NIGMS), NIH, on 02/05/2016. • R35 GM124972–01, ‘‘Novel role of microRNA in directing stem cell fate decision,’’ submitted to NIGMS, NIH, on 11/04/2016. Specifically, ORI found that Respondent knowingly, intentionally, or recklessly falsified and/or fabricated data from the same mouse models or cell lines by reusing the data, with or without manipulation, to represent unrelated experiments from different mouse models or cell lines with different treatments in three hundred eighty-four (384) figure panels in sixteen (16) grant applications. In addition, ORI found that Respondent engaged in research misconduct by knowingly, intentionally, or recklessly falsifying and/or fabricating data included in two (2) PHS-supported published papers. Respondent neither admits nor denies ORI’s findings with respect to the two (2) published papers: • Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ. Leptin-STAT3– G9a signaling promotes obesitymediated breast cancer progression. Cancer Res. 2015 Jun 1;75(11):2375–86. doi: 10.1158/0008–5472.CAN–14–3076. • Wu MJ, Kim MR, Chen YS, Yang JY, Chang CJ. Retinoic acid directs breast cancer cell state changes through regulation of TET2–PKCz pathway. Oncogene 2017 Jun 1;36(22):3193–206. doi: 10.1038/onc.2016.467. Specifically, ORI found that Respondent intentionally, knowingly, or recklessly falsified and/or fabricated: • confocal image data for generation, differentiation, and drug sensitivity of cancer stem cells (CSC) in mouse models and cell lines by reusing the data, with or without manipulation, and relabeling them to represent different experiments in fifty-four (54) figure panels included in fifteen (15) grant applications; • Western blot and co-IP blot images for different protein expression in different mouse models and cell lines by reusing the images, with or without manipulation, and relabeling them to represent different experiments in eighty-one (81) figure panels in thirteen (13) grant applications; VerDate Sep<11>2014 20:05 Dec 15, 2022 Jkt 259001 • figures, charts, and graphs reporting gene expression related results for the global or tissue-related gene expression in mouse models and cell lines with drug treatments by reusing them, with or without manipulation, and relabeling them to represent different experiments in one hundred nineteen (119) figure panels in fifteen (15) grant applications and two (2) published papers; • figures, charts, and graphs about cellular experiment related results for different mouse models and cell lines by reusing them, with or without manipulation, and relabeling them to represent different experiments in fortytwo (42) figure panels in thirteen (13) grant applications; • photomicrographs for different results from different mouse models and cell lines by reusing them, with or without manipulation, and relabeling them to represent different experiments in eighty-five (85) figure panels in fifteen (15) grant applications; • CSC frequency (xenograft tumor formation) data reporting different results from either mouse models or cell lines by reusing and relabeling the same data to represent different experiments in three (3) figure panels in three (3) grant applications. Dr. Chang entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed to the following: (1) Respondent will exclude herself voluntarily for a period of ten (10) years beginning on December 7, 2022 (the ‘‘Exclusion Period’’) from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement or procurement transactions referred to as ‘‘covered transactions’’ in 2 CFR parts 180 and 376 (collectively the ‘‘Debarment Regulations’’). (2) During the Exclusion Period, Respondent will exclude herself voluntarily from serving in any advisory or consultant capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee. (3) Respondent will request that the following papers be corrected: • Cancer Res. 2015 Jun 1; 75(11):2375–86. • Oncogene 2017 Jun 1; 36(22):3193– 206. Respondent will copy ORI and the Research Integrity Officer at PU on the correspondence with the journal(s). Dated: December 13, 2022. Wanda K. Jones, Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health. [FR Doc. 2022–27316 Filed 12–15–22; 8:45 am] BILLING CODE 4150–31–P PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 77129 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel HHS–NIH–CDC–SBIR PHS 2020–1 Phase II: Antiviral drugs to cure chronic hepatitis B virus infection (Topic 84) Date: January 18, 2023. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health 5601 Fishers Lane, Room 3F36 Rockville, MD 20892, (Virtual Meeting). Contact Person: Noto K. Dutta, Ph.D., Scientific Review Officer, Scientific Review Program Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health 5601 Fishers Lane, Room 3F36, Rockville, MD 20852, 240–669–2857 noton.dutta@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: December 12, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–27285 Filed 12–15–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory E:\FR\FM\16DEN1.SGM 16DEN1

Agencies

[Federal Register Volume 87, Number 241 (Friday, December 16, 2022)]
[Notices]
[Page 77129]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27285]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel HHS-NIH-CDC-SBIR PHS 2020-1 Phase 
II: Antiviral drugs to cure chronic hepatitis B virus infection 
(Topic 84)
    Date: January 18, 2023.
    Time: 10:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health 5601 Fishers Lane, Room 3F36 
Rockville, MD 20892, (Virtual Meeting).
    Contact Person: Noto K. Dutta, Ph.D., Scientific Review Officer, 
Scientific Review Program Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health 5601 Fishers Lane, Room 3F36, Rockville, MD 
20852, 240-669-2857 [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: December 12, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-27285 Filed 12-15-22; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.